IP Verse

Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist

Patent No. EP3889181 (titled "Methods For Treating Atopic Dermatitis By Administering An Il-4R Antagonist") was filed by Regeneron Pharmaceuticals on Sep 4, 2013. The application was issued on Apr 24, 2024.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
BOULT WADE TENNANTJan 24, 2025BOULT WADE TENNANT
BRAND MURRAY FULLERJan 24, 2025BRAND MURRAY FULLER
DEHMEL & BETTENHAUSEN PATENTANWALTE PARTMBBJan 24, 2025RUCKERL
HAMPTON KNOWLESJan 24, 2025D YOUNG
LUIGIJan 24, 2025TER MEER STEINMEISTER & PARTNER
MICHALSKI HUTTERMANN & PARTNER PATENTANWALTE MBBJan 24, 2025-
SECERNAJan 23, 2025SECERNA

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3889181

REGENERON PHARMACEUTICALS
Application Number
EP21167811A
Filing Date
Sep 4, 2013
Status
Granted And Under Opposition
Mar 22, 2024
Publication Date
Apr 24, 2024
External Links
Slate, Register , Google Patents